{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin+Lymphomas&page=86",
    "query": {
      "condition": "Non-Hodgkin Lymphomas",
      "page": 86
    },
    "page_size": 10
  },
  "pagination": {
    "page": 86,
    "page_size": 10,
    "total_count": 3574,
    "total_pages": 358,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin+Lymphomas&page=87&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin+Lymphomas&page=85&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-21T02:02:42.583Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02038933",
      "title": "Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma. Non-Hodgkin"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2014-03-05",
      "completion_date": "2020-10-08",
      "has_results": true,
      "last_update_posted_date": "2021-10-14",
      "last_synced_at": "2026-11-21T02:02:42.583Z",
      "location_count": 10,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Atlanta, Georgia + 6 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02038933"
    },
    {
      "nct_id": "NCT04329728",
      "title": "The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lymphoid Malignancies"
      ],
      "interventions": [
        {
          "name": "AVM0703",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AVM Biotechnology Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "12 Years to 95 Years"
      },
      "enrollment_count": 144,
      "start_date": "2020-11-06",
      "completion_date": "2028-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-11-21T02:02:42.583Z",
      "location_count": 11,
      "location_summary": "Duarte, California • Los Angeles, California • Whittier, California + 7 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Weeki Wachee",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04329728"
    },
    {
      "nct_id": "NCT04410900",
      "title": "Vaccine Responsiveness After CAR-T Cell Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B-Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "Wistar Rabies Virus Strain PM-1503-3M Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2020-08-03",
      "completion_date": "2025-08-31",
      "has_results": false,
      "last_update_posted_date": "2025-09-08",
      "last_synced_at": "2026-11-21T02:02:42.583Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04410900"
    },
    {
      "nct_id": "NCT03229200",
      "title": "Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Lymphoma, B-Cell",
        "Lymphoma, Non-Hodgkin",
        "Leukemia, B-cell",
        "Graft Vs Host Disease",
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharmacyclics Switzerland GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 297,
      "start_date": "2017-05-22",
      "completion_date": "2027-05-10",
      "has_results": false,
      "last_update_posted_date": "2025-10-30",
      "last_synced_at": "2026-11-21T02:02:42.583Z",
      "location_count": 34,
      "location_summary": "Burbank, California • Duarte, California • La Jolla, California + 27 more",
      "locations": [
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03229200"
    },
    {
      "nct_id": "NCT05994157",
      "title": "Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "CD38-SADA:177Lu-DOTA Complex",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Y-mAbs Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2025-04-21",
      "completion_date": "2025-10-15",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-11-21T02:02:42.583Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Grand Rapids, Michigan + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05994157"
    },
    {
      "nct_id": "NCT01926665",
      "title": "Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 2,
      "start_date": "2014-06-17",
      "completion_date": "2017-09-17",
      "has_results": false,
      "last_update_posted_date": "2017-09-19",
      "last_synced_at": "2026-11-21T02:02:42.583Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01926665"
    },
    {
      "nct_id": "NCT01421667",
      "title": "A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma, B-Cell",
        "Lymphoma, Large B-Cell, Diffuse",
        "Lymphoma, Non-Hodgkin",
        "Lymphoma, T-Cell"
      ],
      "interventions": [
        {
          "name": "brentuximab vedotin",
          "type": "DRUG"
        },
        {
          "name": "rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seagen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 176,
      "start_date": "2011-08",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2016-11-28",
      "last_synced_at": "2026-11-21T02:02:42.583Z",
      "location_count": 33,
      "location_summary": "Birmingham, Alabama • Duarte, California • Oxnard, California + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01421667"
    },
    {
      "nct_id": "NCT02328014",
      "title": "Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Hodgkins Lymphoma",
        "Multiple Myeloma",
        "B-All"
      ],
      "interventions": [
        {
          "name": "Acalabrutinib",
          "type": "DRUG"
        },
        {
          "name": "ACP-319",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Acerta Pharma BV",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2014-12-20",
      "completion_date": "2025-10-30",
      "has_results": true,
      "last_update_posted_date": "2025-12-09",
      "last_synced_at": "2026-11-21T02:02:42.583Z",
      "location_count": 7,
      "location_summary": "Orange, California • Bethesda, Maryland • Rochester, New York + 4 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02328014"
    },
    {
      "nct_id": "NCT02446236",
      "title": "Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hackensack Meridian Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2015-06-18",
      "completion_date": "2027-01",
      "has_results": true,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-11-21T02:02:42.583Z",
      "location_count": 1,
      "location_summary": "Hackensack, New Jersey",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02446236"
    },
    {
      "nct_id": "NCT00577993",
      "title": "Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Novantrone",
          "type": "DRUG"
        },
        {
          "name": "Decadron",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Interferon",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Bleomycin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Ara-C",
          "type": "DRUG"
        },
        {
          "name": "Methyl-Prednisolone",
          "type": "DRUG"
        },
        {
          "name": "Procarbazine",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "76 Years",
        "sex": "ALL",
        "summary": "Up to 76 Years"
      },
      "enrollment_count": 210,
      "start_date": "1998-03-16",
      "completion_date": "2017-08-24",
      "has_results": true,
      "last_update_posted_date": "2020-11-16",
      "last_synced_at": "2026-11-21T02:02:42.583Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00577993"
    }
  ]
}